Changing therapeutic paradigms in glaucoma management

Bibliography

• RITCH R, SHIELDS MB, KRUPIN T: Preface. In: The Glauco-mas (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St. Louis, USA (1996):xix-xx.
   Google Scholar
• QUIGLEY HA, ADDICKS EM: Chronic experimental glaucoma in primates II. Effect of extended intraocular pressure elevation on optic nerve head and axon transport. Invest. Ophthalmol. Vis. Sci. (1980) 19:137–152.
   Google Scholar
• QUIGLEY HA, ADDICKS EM, GREEN WR, MAUNEMEE AE: Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Am. J. Ophthalmol (1981) 99:635–649.
   Google Scholar
• QUIGLEY HA, NICKELLS RW, KERRIGAN LA et al.: Retinal ganglion cell death in experimental glaucoma and af-ter axotomy occurs by apoptosis. Invest. Ophthalmol Vis. Sci. (1995) 36:774–786.
   PubMed Web of Science ®Google Scholar
• NICKELLS RW: Retinal ganglion cell death in glaucoma: the how, the why and the maybe. Glaucoma (1996) 5:345–356.
   PubMed Web of Science ®Google Scholar
• OKISAKA S, MURAKAMI A, MIZUKAWA A, ITO J: Apopto-sis in retinal ganglion cell decrease in human glauco-matous eyes. Jpn.J. Ophthalmol. (1997) 41(2):84–88.
   PubMed Web of Science ®Google Scholar
• THYLEFORS B, NÉGREL AD: The global impact of glau-coma. Bull. World Health Org. (1994) 72(3):323–326.
   PubMed Web of Science ®Google Scholar
• QUIGLEY HA: Number of people with glaucoma world-wide. Br. J. Ophthalmol (1996) 80:389–393.
   PubMed Web of Science ®Google Scholar
• GEORGOPOULOS G, ANDREANOS D, LIOKIS N et al: Risk factors in ocular hypertension. Eur. J. Ophthalmol. (1997) 7(4):357–363.
   PubMedGoogle Scholar
• HIGGINBOTHAM EJ: Glaucoma: a preventable cause of blindness. Md. Med. J. (1997) 46 (8) :412–414.
   PubMedGoogle Scholar
• HAEFLIGER IO: Risk factors associated with glaucoma. Kiln. Monatsbl. Augenheilkd. (1997) 210(5):265–268.
   PubMed Web of Science ®Google Scholar
• STEWART WC, SINE C, SUTHERLAND S, STEWART JA: To-tal cholesterol and high-density lipoprotein levels as risk factors for increased intraocular pressure. Am. J. Ophthalmol (1996) 122 (4) :575–577.
   PubMed Web of Science ®Google Scholar
• COCKBURN DM: Does reduction of intraocular pres-sure (lOP) prevent visual field loss in glaucoma? Am. J. Optom. Phys. Opt. (1983) 60(8):705–711.
   PubMed Web of Science ®Google Scholar
• SCHULZER M, DRANCE SM, CARTER CM ETAL.: Biostatis-tical evidence for two distinct chronic open-angle glaucoma populations. Br. J. Ophthalmol. (1990) 74:196–200.
   Google Scholar
• KASS MA, GORDON MO, HOFF MR et al: Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A random-ised, double-masked, long-term clinical trial. Arch. Ophthalmol. (1989) 107(10:1590–1598.
   PubMedGoogle Scholar
• EPSTEIN DL, KRUG JH, Jr., HERTZMARK E, REMIS LL, EDELSTEIN DJ: A long-term clinical trial of timolol ther-apy versus no treatment in the management of glau-coma suspects. Ophthalmology (1989) 96 (10) :1460–1467.
   Google Scholar
• LAMPING KA, BELLOWS AR, HUTCHINSON BT, AFRAN SI: Long-term evaluation of initial filtration surgery. Oph-thalmology (1986) 93(0:91–101.
   PubMed Web of Science ®Google Scholar
• MIGDAL C, GREGORY W, HITCHINGS R: Long-term func-tional outcome after early surgery compared with la-ser and medicine in open-angle glaucoma. Ophthalmology (1994) 101(101651–1656.
   Web of Science ®Google Scholar
• SCHUMER RA, PODOS SM: The nerve of glaucoma! Arch. Ophthalmol. (1994) 112:37–44.
   Web of Science ®Google Scholar
• CAPRIOLI J: Neuroprotection of the optic nerve in glau-coma. Acta. Ophthalmol. Scand. (1997) 75(4):364–367.
   PubMedGoogle Scholar
• SPAETH GL: Proper outcome measurements regarding glaucoma: the inadequacy of using intraocular pres-sure alone. Eur. j Ophthalmol. (1996) 6(2):101–105.
   PubMedGoogle Scholar
• RADIUS RL, ANDERSON DR: Rapid axonal transport in primate optic nerve. Disruption of pressure-induced interuption. Arch. Ophthalmol. (1981) 99:650–654.
   PubMed Web of Science ®Google Scholar
• FLAMMER J: The vascular concept of glaucoma. Sun'. Ophthalmol. (1994) 38:3–6.
   PubMedGoogle Scholar
• HITCHINGS RA, WITH DISCUSSION BY O'BRIEN, O'SULLI-VAN, WATSON, KHAE, JAY: Intraocular pressure and circulation at the disc in glaucoma. Acta Ophthalmol. Scand. (1997) 75(220) (Suppl.):15–22.
   Google Scholar
• YAMAMOTO T, KITAZAWA Y: Vascular pathogenesis of normal-tension glaucoma: a possible pathogenetic factor, other than intraocular pressure, of glaucoma-tous optic neuropathy. Prog. Ret. Eye Res. (1998) 17 (1):127–143.
   PubMed Web of Science ®Google Scholar
• DREYER EB: A proposed role for excitotoxicity in glau-coma. J. Glaucoma (1998) 7(0:62–67.
   PubMed Web of Science ®Google Scholar
• DAMJI KF, ALLINGHAM RR: Molecular genetics is revolu-tionizing our understanding of ophthalmic disease. Am. J. Ophthalmol. (1997) 124(4):530–543.
   PubMed Web of Science ®Google Scholar
• SARFARAZI M: Recent advances in molecular genetics of glaucomas. Hum. Mol. Genet. (1997) 6(10):1667–1677.
   PubMed Web of Science ®Google Scholar
• DREYER EB, GROSSKREUTZ CL: Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Clin. Neurosci. (1997) 4 (5):270–273.
   PubMedGoogle Scholar
• VORWERK CK, LIPTON SA, ZURAKOWSKI D et al.: Chronic low-dose glutamate is toxic to retinal gan-glion cells. Invest. Ophthalmol Vis. Sci. (1996) 37(8): 1618–1624.
   PubMed Web of Science ®Google Scholar
• LYNCH DR, DAWSON TM: Secondary mechanisms in neuronal trauma. Curr. Opin. Neurol. (1994) 7:175–186.
   Web of Science ®Google Scholar
• MCLOON SC: Response of astrocytes in the visual sys-tem to Walerian degeneration: an immunohistochemical analysis of laminin and glialfi-brillary acidic protein. Exp. Neurol (1986) 91:613–621.
   PubMed Web of Science ®Google Scholar
• SCHÜTTE M, CHEN S, BAYER A, WOLOSIN JM, MITTAG T: Pathological changes in the rat retina in response to elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci. (1997) 38(4):(S1). Abstract 792.
   Google Scholar
• HERNANDEZ MR, PENA JOD, DOYLE MC et al: Astrocytes in glaucomatous optic neuropathy: in situ and in vitro. 2nd International Glaucoma Symposium. Handbook (1998):92. Abstract.
   Google Scholar
• STONE EM, FINGERT JH, ALWARD WLM et al: Identifica-tion of a gene that causes primary open angle glau-coma. Science (1997) 275:668–670.
   PubMed Web of Science ®Google Scholar
• BREZIN AP, BECHETOILLE A, HAMARD P et al.: Genetic heterogeneity of primary open angle glaucoma and ocular hypertension: linkage to GLC1A associated with an increased risk of severe glaucomatous optic neuro-pathy. J. Med. Genet. (1997) 34:546–552.
   PubMed Web of Science ®Google Scholar
• AMERICAN ACADEMY OF OPHTHALMOLOGY: Basic and Clinical Science Course: Glaucoma. American Academy of Ophthalmology, SF, USA (1997–1998). Section 10:104–113.
   Google Scholar
• ALLEN RC. Medical management of glaucoma. In: Prin-ciples and Practices of Ophthalmology. Albert DM, Jakobiec FA (Eds.), (1993):1569–1588.
   Google Scholar
• DIAMOND JP: Systemic adverse effects of topical oph-thalmic agents. Implications for older patients. Drugs Aging (1997) 11(5):352–360.
   PubMed Web of Science ®Google Scholar
• DIGGORY P, FRANKS W: Medical treatment of glaucoma - a reappraisal of the risks. Br. J. Ophthalmol (1996) 80(1):85–89.
   PubMed Web of Science ®Google Scholar
• NETLAND PA, CHATURVEDI N, DREYER EB: Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am. J. Ophthalmol (1993) 115 (5) :608–613.
   PubMed Web of Science ®Google Scholar
• GASSER P, FLAMMER J: Short and long-term effect of nifedipine on the visual field in patients with pre-sumed vasospasm. J. Int. Med. Res. (1990) 18:334–339.
   PubMed Web of Science ®Google Scholar
• GASPAR AZ, FLAMMER J, HENDRICKSON P: Influence of nifedipine on the visual fields of patients with optic nerve head diseases. Eur. J. Ophthalmol. (1994) 4:24–28.
   PubMedGoogle Scholar
• SCHWARTZ M, BELKIN M, YOLES E, SOLOMON A: Poten-tial treatment modalities for glaucomatous neuropa-thy: neuroprotection and neuroregeneration. J. Glaucoma (1996) 5(6):427–432.
   PubMed Web of Science ®Google Scholar
• DREYER EB: The potential for neuroprotection in glau-coma. Ophthalmol. Clin. N Am. (1997) 10(3):365–376.
   Google Scholar
• SUGRUE MF: New approaches to antiglaucoma ther-apy. J. Med. Chem. (1997) 40(18):2793–2809.
   PubMed Web of Science ®Google Scholar
• LIESEGANG TJ: Glaucoma: changing concepts and fu-ture directions. Mayo Clin. Proc. (1996) 71:689–694.
   PubMed Web of Science ®Google Scholar
• MCKINNON SJ. Glaucoma, apoptosis, and neuroprotec-tion. Curr. Opin. Ophthalmol. (1997) 8(2):28–37.
   PubMedGoogle Scholar
• YOLES E, SCHWARTZ M: Potential neuroprotective ther-apy for glaucomatous optic neuropathy. Sun'. Ophthal-mol. (1998) 42(4):367–372. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• WEN R, CHENG T, LI Y, CAO W, STEINBERG RH: Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ame-liorate light damage. J. Neurosci. (1996) 16(19)5986–5992.
   Google Scholar
• YOLES E, MULER S, SCHWARTZ M et al.: Injury-inducedsecondary degeneration of rat optic nerve can be at-tenuated by a2-adrenoceptor agonists AGN 191103 and brimonidine. Invest. Ophthalmol. Vis. Sci. (1996) 37(3):S114. Abstract 540.
   Google Scholar
• HASSON D, LAI RK, CHUN T, WHEELER L: Functionalprotection of rat retina from ischaemic injury by bri-monidine. Soc. Neurosci. (1997) 23(1–2):168. Abstract.
   Google Scholar
• LAIR, HASSON D, CHUN T, WHEELER L: Neuroprotectiveeffect of ocular hypotensive agent brimonidine. Xlth Congress of the European Society of Ophthalmology ISOEI: Proceedings (1997)439–444.
   Google Scholar
• WHEELER LA, LAI RK: Use of pharmacological agents tomodulate neuronal cell death and injury. 2nd Interna-tional Glaucoma Symposium. Handbook (1998)99. Ab-stract.
   Google Scholar
• GIESER SC, JUZYCH M, ROBIN AL et al: Clinical pharma-cology of adrenergic drugs. In: The Glaucomas (2nd Edi-tion). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St. Louis, USA (1996):1425–1448.
   Google Scholar
• NARDIN GF, ZIMMERMAN TJ: Ocular cholinergic agents.In: The Glaucomas (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St. Louis, USA (1996):1399–1407.
   Google Scholar
• SORENSEN SJ, ABEL SR: Comparison of the ocular beta-blockers. Ann. Pharmacother. (1996) 30:43–54.
   PubMed Web of Science ®Google Scholar
• STEWART WC, CASTELLI WP: Systemic side effects oftopical beta-adrenergic blockers. Clin. Cardiol (1996) 19:691–697.
   PubMed Web of Science ®Google Scholar
• GRANT WM: Toxicology of the Eye (2nd Edition). ThomasCC (Ed.), Springfield, Illinois, USA (1974):833–835.
   Google Scholar
• HOSTYN P, LE REBELLER MJ, TRIQUAND C: THE STUDYGROUP: Fixed combination of carteolol and pilocarp-ine eye-drops: a double-blind randomised cross-over trial versus carteolol alone on intra-ocular pressure. Eur. J. Ophthalmol. (1996) 6:17–20.
   PubMedGoogle Scholar
• REYES E, IZQUIERDO NJ, BLASINI M: Adverse drug reac-tions associated with glaucoma medications. Biol. Asoc. Med. (1997) 89:51–55.
   Google Scholar
• KEATES EH, BAARVELDT G, CHAPMAN BS et al.: Long-term efficacy and safety of dipivefrin in open-angle glaucoma and ocular hypertension. In: Acta XXV Con-cilium Ophthalmologicum. Blondi F et al. (Eds.), Kugler and Ghedini, Rome, Italy (1988):1448–1452.
   Google Scholar
• SCHMETTERER L, STRENN K, FINDL 0 et al: Effects of an-tiglaucoma drugs on ocular haemodynamics in healthy volunteers. Clin. Pharmacol. Ther. (1997) 61(5):583–595.
   PubMed Web of Science ®Google Scholar
• VAN BUSKIRK EM, FRAUNFELDER FT: Ocular beta-blockers and systemic effects. Am. J. Ophthalmol. (1994) 98:623–624.
   Web of Science ®Google Scholar
• BOGER WP, III: Short-term escape and long-term drift. The dissipation effects of the beta-adrenergic blocking agents. Surv. Ophthalmol (1983) 28:235–240.
   Google Scholar
• LIN LI, GALIN MA, OBSTBAUM SA et al.: Long-term ti-molol therapy. Surv. Ophthalmol. (1979) 23(6):377–380.
   PubMed Web of Science ®Google Scholar
• STEINERT RF, THOMAS JV, BOGER WP: Long-term drift and continued efficacy after multiyear timolol. Arch. Ophthalmol (1981) 99:100.
   PubMed Web of Science ®Google Scholar
• KASS MA: Efficacy of combining timolol with other an-tiglaucoma medications. Surv. Ophthalmol. (1983) 28:274–279.
   PubMedGoogle Scholar
• GANDOLFI SA, VECCHI M: Serial administration of ad-renergic antagonist and agonist (pulsatile therapy) re-duces the incidence of longterm drift to timolol in humans. Invest. Ophthalmol. Vis. Sci. (1996) 37:684–688.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WH, FUKSBRUMER MS, TANNENBAUM M: Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J. Clin. Pharmacol. (1994) 34(8):795–803.
   PubMed Web of Science ®Google Scholar
• MCMAHON CE, SHAFFER RN, HOSKINS HD, Jr. et al: Ad-verse effects experienced by patients taking timolol. Am. J. Ophthalmol. (1979) 78:736.
   Web of Science ®Google Scholar
• VAN BUSKIRK EM: Adverse reactions from timolol ad-ministration. Ophthalmology (1980) 87:447.
   PubMed Web of Science ®Google Scholar
• ALLEN RC, HERTZMARK E, WALKER AM et al.: A double-masked comparison of betaxolol vs. timolol in the treatment of open-angle glaucoma. Am. J. Ophthalmol (1986) 101:535–541.
   Google Scholar
• WEINREB RN, VAN BUSKIRK EM, CHERNIAK R et al.: Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am. J. Ophthalmol (1988) 106:162–167.
   PubMed Web of Science ®Google Scholar
• HARRIS LS, GREENSTEIN SH, BLOOM AF: Respiratory dif-ficulties with betaxolol [letter]. Am. J. Ophthalmol (1986) 102:274.
   PubMed Web of Science ®Google Scholar
• BALL S: Congestive heart failure from betaxolol. Case report. Arch. Ophthalmol (1987) 105 (3):320.
   PubMed Web of Science ®Google Scholar
• BROOKS AMV, GILLIES WE: Ocular beta-blockers in glaucoma management. Drugs Aging (1992) 2:208–221.
   PubMed Web of Science ®Google Scholar
• HESTER RK, CHEN Z, BECKER EJ, MCLAUGHLIN M, DE-SANTIS L: The direct vascular relaxing action of betax-olol, carteolol, and timolol in porcine long posterior ciliary arteries. Surv. Ophthalmol. (1994) 38:S125–S134.
   PubMedGoogle Scholar
• COLLIGNON-BRACH J: Long-term effect of topical beta-blockers on intraocular pressure and visual field sen-sitivity in ocular hypertension and chronic open-angle glaucoma. Surv. Ophthalmol. (1994) 38:149–155.
   Google Scholar
• FLAMMER J: Therapeutic aspects of normal-tension glaucoma. Curr. Opin. Ophthalmol. (1993) 4:58–64.
   Web of Science ®Google Scholar
• HARRIS A, SPAETH GL, SERGOTT RC et al.: Retrobulbar arteriolar haemodynamic effects of betaxolol and ti-molol in normal-tension glaucoma. Am. J. Ophthalmol (1995) 120(2):168–175.
   PubMed Web of Science ®Google Scholar
• AREND 0, HARRIS A, KAGEMANN C, MARTIN BJ: Circula-tory effects on retinal vasculature of betaxolol versus © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7) dorzolamide in patients with normal tension glau-coma. Invest. Ophthalmol. Vis. ScL (1998) 39(4):S1000. Ab-stract 4620.
   Google Scholar
• SCHMETTERER L, LEXER F, UNFRIED C, SATTMANN H, FERCHER A: Topical measurement of fundus pulsa-tions. Opt. Eng. (1996) 34:711–716.
   Web of Science ®Google Scholar
• BOLES-CARENINI AB, SIBOUR G, BOLES-CARENINI B: Dif-ferences in the long-term effect of timolol and betax-olol on pulsatile ocular blood flow. Sun'. Ophthalmol. (1994) 38(Suppl.):S118–S124.
   Google Scholar
• GUPTA A, CHEN HC, RASSAM SM, KOHNER EM: Effect ofbetaxolol on the retinal circulation in eyes with ocular hypertension: a pilot study. Eye (1994) 8(6)668–671.
   Google Scholar
• OSBORNE NN, CAZEVIEILLE C, CARVALHO AL, LARSEN AK, DESANTIS L: In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. (1997) 751(0:113–123.
   PubMed Web of Science ®Google Scholar
• LIPPA EA: Carbonic anhydrase inhibitors. In: The Glau-comas (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St. Louis, USA (1996):1463–1480.
   Google Scholar
• BRANDT JD: Carbonic anhydrase inhibitors. CIAO J. (1991) 1 7 (2):136–138.
   Google Scholar
• MAUS TL, LARSSON L-I, MCLAREN JAN et al: Comparison of dorzolamide and acetazolamide as supressors of aqueous humour flow in humans. Arch. Ophthalmol. (1997) 115:45–49.
   PubMed Web of Science ®Google Scholar
• HIGGINBOTHAM EJ. Dorzolamide: a brief overview. Chibret.Int.J. Ophthalmol. (1994) 10(3):50–53.
   Google Scholar
• STRAHLMAN E, TIPPING R, VOGEL R, FOR THE INTERNA-TIONAL DORZOLAMIDE STUDY GROUP: A double-masked, randomised 1-year study comparing dorzola-mide (Trusopt), timolol, and betaxolol. Arch. Ophthal-mol. (1995) 113(8):1009–1016.
   PubMed Web of Science ®Google Scholar
• STRAHLMAN E, TIPPING R, VOGEL R, FOR THE DORZO-LAMIDE DOSE-RESPONSE STUDY GROUP: A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am. J. Oph-thalmol (1996) 12 2 (2):183–194.
   Google Scholar
• BALFOUR JA, WILDE MI: Dorzolamide. A review of its pharmacology and therapeutic potential in the man-agement of glaucoma and ocular hypertension. Drugs Aging (1997) 10(5):384–403.
   Google Scholar
• DONOHUE EK, WILENSKY JT: Dorzolamide: a review. Semin. Ophthalmol (1997) 12 (3) :119–126.
   Google Scholar
• CAMRAS CB, FOR THE BRINZOLAMIDE PRIMARY THER-APY STUDY GROUP: A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1% compared to TID-dosed dorzolamide 2% and BID-dosed timolol 0.5%. Invest. Ophthalmol. Vis. Sci. (1997) 38(4):5560. Abstract 2606.
   Google Scholar
• MARCH WF, SILVER LH, FOR THE BRINZOLAMIDE LONG-TERM STUDY GROUP: The long-term safety and efficacy of brinzolamide (AZOPe), a new topical carbonic an-hydrase inhibitor, in patients with open-angle glau-coma and ocular hypertension. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):S199. Abstract 940.
   Google Scholar
• STEWART R, FOR THE BRINZOLAMIDE COMFORT STUDYGROUP: The ocular comfort of TID-dosed brinzola-mide 1.0% compared to TID-dosed dorzolamide 2% in patients with primary open-angle glaucoma or ocular hypertension. Invest. Ophthalmol. Vis. Sci. (1997) 38(4):5559. Abstract 2603.
   Google Scholar
• WILKERSON M, CYRLIN M, LIPPA EA et al Four-week safety and efficacy study of dorzolamide, a novel, ac-tive topical carbonic anhydrase inhibitor. Arch. Oph-thalmol. (1993) 11 1 (10) 1343–1350
   Google Scholar
• KONOWAL A, EPSTEIN R, DENNIS R et al.: Irreversiblecorneal decompensation in patients treated with topi-cal dorzolamide. Invest. Ophthalmol Vis. Sci. (1996) 3 7 (3):S79.
   Google Scholar
• EGAN CA, HODGE DO, MCLAREN JW, BOURNE WM: Ef-fect of dorzolamide on corneal endothelial function in normal human eyes. Invest. Ophthalmol. Vis. Sci. (1998) 39(1)23–29.
   Google Scholar
• BIOLLAZ J, MUNAFO A, BUCLIN T et al: Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur. J. Clin. Pharmacol. (1995) 47(5):455–460.
   PubMed Web of Science ®Google Scholar
• HARRIS A, MARTIN BJ, SHOEMAKER JA: Regulation of retinal blood flow during blood gas perfusion. J. Glau-coma (1994) 3 (Suppl. 1):S82–S89.
   Google Scholar
• HARRIS A, AREND 0, AREND S, MARTIN B: Effects of topi-cal dorzolamide on retinal and retrobulbar haemody-namics. Acta Ophthalmol Scand. (1996) 74(6):569–572.
   PubMedGoogle Scholar
• GRUNWALD JE, MATHUR S, DUPONT J: Effects of dorzo-lamide hydrochloride 2% on the retinal circulation. Acta Ophthalmol. Scand. (1997) 75 (3):236–238.
   PubMedGoogle Scholar
• CLINESCHMIDT CM, STRAHLMAN ER, ANDERSON K et al: Comparison of a fixed combination of dorzolamide and timolol (BID) to concomitant administration of dorzolamide (TID) plus timolol (BID) in patients with open-angle glaucoma for three months. Invest. Ophthal-mol. Vis. Sci. (1995) 36(4):5736. Abstract 3405.
   Google Scholar
• STROHMAIER K, SNYDER E, ADAMSONS I: Long-term safety and efficacy of Cosope- a fixed combination of dorzolamide and timolol. Invest. Ophthalmol Vis. ScL (1996) 37(3):5069.
   Web of Science ®Google Scholar
• TORIS CB, CAMRAS CB: Prostaglandins. A new class of aqueous outflow agents. Ophthalmol. Clin. N Am. (1997) 10(3)335–355.
   Google Scholar
• PATEL SS, SPENCER CM: Latanoprost - a review of its pharmacological properties, clinical efficacy and tol-erability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging (1996) 9(5):363–378.
   PubMed Web of Science ®Google Scholar
• BITO LZ: Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv. Ophthalmol. (1997) 41 (S2) :S1–514.
   PubMed Web of Science ®Google Scholar
• BASU S, SJOQUIST B, STJERNSCHANTZ J et al.: Corneal permeability to and ocular metabolism of phenyl sub-stituted prostaglandin esters in vitro. Prostagland. Leu-kotriene Essen. Fat t y Acids (1994) 50:161-168. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• STJERNSCHANTZ J, SELEN G, SJOQUIST B et al.: Preclini-cal pharmacology of latanoprost, a phenyl-sustituted PGF2a analogue. Adv. Prostag. Thromb. Leuko. Res. (1995) 23:513–518.
   PubMedGoogle Scholar
• GABELT B'AT, KAUFFMAN PL: Prostaglandin F2a in-creases uveoscleral outflow in the cynolmolgus mon-key. Exp. Eye Res. (1989) 49:489–402.
   Google Scholar
• TORTS CB, CAMRAS CB, YABLONSKI ME, BRUBAKER RF: Effects of exogenous prostaglandins on aqueous hu-mour dynamics and blood aqueous barrier function. Sun'. Ophthalmol. (1997) 41 (2):S69–S76.
   Google Scholar
• NILSSON SFV: The uveoscleral outflow routes. Eye (1997) 11:149–154.
   PubMed Web of Science ®Google Scholar
• WEINREB RN, KASHIGAWA K, KASHIGAWA F, TSUKA-HARA S, LINDSEY JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. 1/is. Sci. (1997) 38(13)2772–2780.
   Google Scholar
• ALM A, CAMRAS CB, WATSON PG: Phase III latanoprost studies in Scandinavia, the United Kingdom, and the United States. Sun'. Ophthalmol. (1997) 41(2):5105–5110.
   Google Scholar
• ALMA, STJERNSCHANTZ J, AND THE SCANDINAVIAN LA-TANOPROST STUDY GROUP: Effects on intraocular pressure and side-effects of 0.005% latanoprost once daily, evening or morning. A comparison with ti-molol. Ophthalmology (1995) 102:1743–1752.
   Google Scholar
• DIESTELHORST M, KRIEGLSTEIN GK, LUSKY M, NAGA-SUBRAMANIAN S: Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2a ana-logue. Sun'. Ophthalmol. (1997) 41 (2):S77–S82.
   Google Scholar
• SEVERIN T: The efficacy and tolerability of latanoprost in primary open angle glaucoma patients. Invest. Oph-thalmol 1/is. Sci. (1998) 39(4):5256. Abstract 1165.
   Google Scholar
• HYONG PFJ, RULO A, GREVE EL, WATSON P, ALM A: The additive intraocular pressure-lowering effect of la-tanoprost in combined therapy with other ocular hy-potensive agents. Sun'. Ophthalmol (1997) 41 (2):S93–S98.
   PubMed Web of Science ®Google Scholar
• WISTRAND PJ, STJERNSCHANTZ J, OLSSON K: The inci-dence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Sun'. Ophthal-mol. (1997) 41(S2):5129–S138.
   Google Scholar
• SELEN G, STJERNSCHANTZ J, RESUL B: Prostaglandin-induced iridial pigmentation in primates. Surv. Oph-thalmol (1997) 41(2):S125–S128.
   PubMed Web of Science ®Google Scholar
• CAMRAS CB, ALM A: Initial clinical studies with prosta-glandins and their analogues. Sun'. Ophthalmol. (1997) 41(2):S61–575.
   PubMed Web of Science ®Google Scholar
• WAND M: Latanoprost and hyperpigmentation of eye-lashes [letter]. Arch. Ophthalmol. (1997) 115 (9):1206–1208.
   PubMed Web of Science ®Google Scholar
• JOHNSTONE MA: Hypertrichosis and increased pig-mentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients tretaed with unilat-eral topical latanoprost. Am. J. Ophthalmol. (1997) 124:544–547.
   PubMed Web of Science ®Google Scholar
• WATSON P, STJERNSCHANZ J, AND THE LATANOPROST STUDY GROUP: A six month randomised double-masked study comparing latanoprost to timolol in open-angle glaucoma and ocular hypertension. Oph-thalmology (1996) 103:126–137.
   PubMed Web of Science ®Google Scholar
• WARWAR RE, BULLOCK JD, BALLAL D: Cystoid macular edema and anterior uveitis associated with latano-prost use. Ophthalmology (1998) 105(2):263–268.
   PubMed Web of Science ®Google Scholar
• GADDIE TB, BENNETT DW: Cystoid macular edema as-sociated with the use of latanoprost. J. Am. Optom. As-soc. (1998) 69(2):122–128.
   PubMedGoogle Scholar
• ROWE JA, HATTENHAUER MG, HERMAN DC: Adverse side effects associated with latanoprost. Am. J. Ophthal-mol. (1997) 124(5):683–685.
   PubMed Web of Science ®Google Scholar
• LUSKY M, TICHO U, GLOVINSKY J et al.: A comparative study of ten dose regimens of latanoprost in patients with elevated intraocular pressure. Ophthalmology (1997) 104:1720–1724.
   PubMed Web of Science ®Google Scholar
• WATSON PG, FOR THE LATANOPROST STUDY GROUP: Latanoprost. Two years' experience of its use in the United Kingdom. Ophthalomology (1998) 105:82–87.
   Google Scholar
• NICOLELA MT, BUCKLEY AR, WALMAN BE, DRANCE SM: A comparative study of the effects of timolol and latano-prost on blood flow velocity of the retrobulbar vessels. Am. J. Ophthalmol. (1996) 122:784–789.
   PubMed Web of Science ®Google Scholar
• NICHOLL JE, MYERS JS, SAMUEL F, KATZ LJ, SPAETH GL: Effect of latanoprost on retinal blood flow as measured by the Heidelberg retina flowmeter. Invest. Ophthalmol 1/is. Sci. (1998) 39(4):S270. Abstract 1228.
   Google Scholar
• GEORGOPOULOS G, DIESTELHORST M, FISCHER R, ROUKENEN P, KREIGLSTEIN GK: Short-term effect of la-tanoprost on ocular blood flow. Invest. Ophthalmol. 1/is. Sci. (1998) 39(4):5265. Abstract 1205.
   Google Scholar
• SAKURAI M, ARAIE M, OSHIKA T et al.: Effects of topical application of UF-021, a novel prostaglandin deriva-tive, on aqueous humour dynamics in normal human eyes. Jpn. JOphthalmol. (1991) 35(2):156–165.
   PubMed Web of Science ®Google Scholar
• AZUMA I, MASUDA K, KITAZAWA Y et al.: Double-masked comparative study of UF-021 and timolol oph-thalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Ophthalmology (1993) 37:514–525.
   Web of Science ®Google Scholar
• HARIA M, SPENCER CM: Unoprostone (isopropyl uno-prostone). Drugs Aging (1996) 9(3):213–218. Discussion 219–220.
   Google Scholar
• YOSHIDA K, TANIHARA H, OKAZAKI K, HIROI K, HONDA Y: Clinical characteristics in hypotensive effects of isoprolyl unoprostone in glaucomatous eyes. Invest. Ophthalmol Vis. Sci. (1998) 39(4):5257. Abstract 1174.
   Google Scholar
• YAMAMOTO T, KITAZAWA Y, AZUMA I, MASUDA K: Clinical evaluation of UF-021 (RESCULe; isopropyl unoprostone). Sun'. Ophthalmol. (1997) 41 (2):S99–S104.
   Google Scholar
• KIMURA T, ONO J, ISHII R et al.: The effect of isopropyl unoprostone on the concomitant application of 0-blocker, dipivefrin, and pilocarpine. Invest. Ophthal-mol. 1/is. Sci. (1998) 39(4):(S258). Abstract 1175. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• YAMAMOTO T, KITAZAWA Y: Iris-color change devel-oped after topical isopropyl unoprostone treatment. J. Glaucoma (1997) 6(6):430–432.
   PubMed Web of Science ®Google Scholar
• TOMIDOKORO A, ARAIE M, TAMAKI Y, TOMITA K: In vivo measurement of iridial circulation using laser speckle phenomenon. Invest. Ophthalmol. Vis. ScL (1998) 39(2) 364–371.
   PubMed Web of Science ®Google Scholar
• KOJIMA S, SUGIYAMA T, AZUMA I, KONISHI N, FUJII H: Effect of topically applied isopropyl unoprostone on microcirculation in the human ocular ftmdus evalu-ated with a laser speckle microcirculation analyser. Nippon GankaGakkai Zasshi (1997) 101(7):605–610.
   PubMedGoogle Scholar
• NISHI A, IDO M, ITO K, SASOH M, UJI Y: The effect of unoprostone eye drops on blood flow velocity of retro-bulbar vessels in normal tension glaucoma. Invest. Ophthalmol. Vis. Sci. (1998) 39(4) :S999. Abstract 4616.
   Google Scholar
• HODAPP E, KOLKER A, KASS M et al.: The effect of topical clonidine on intraocular pressure. Arch. Ophthalmol. (1981) 99:1208–1211.
   PubMed Web of Science ®Google Scholar
• NOVACK GD, ROBIN AL, DERRICK RJ: New medical treat-ments for glaucoma. Int. Ophthalmol. Clin. (1993) 33:183–202.
   PubMedGoogle Scholar
• TORIS CB, TAFOYA ME, CAMRAS CB, YABLONSKI ME: Ef-fects of apraclonidine on aqueous humour dynamics in human eyes. Ophthalmology (1995) 102 (3) :456–461.
   PubMed Web of Science ®Google Scholar
• British National Formulmy. British Medical Association and Royal Pharmaceutical Society of Great Britain (1996) 32:441.
   Google Scholar
• CARDAKLI F, SMYTHE B, EISELE J et al.: Effect of chronic apraclonidine treatment on intraocular pressure in advanced glaucoma. J. Glaucoma (1992) 1:271–278.
   PubMedGoogle Scholar
• LISH A, CAMRAS C, PODOS S: Effect of apraclonidine on intraocular pressure in glaucoma patients receiving maximally tolerated medication. J. Glaucoma (1992) 1:19–22.
   Google Scholar
• YeKSEL N, GeLER C, AGLAR Y et al.: Apraclonidine and clonidine: a comparison of efficacy and side-effects in normal and ocular hypertensive volunteers. Int. Oph-thalmol (1992) 16(4-5):337–342.
   PubMed Web of Science ®Google Scholar
• ROBBIN AL: Questions concerning the role of apraclo-nidine in the management of glaucoma. Arch. Ophthal-mol. (1995) 113:712–714.
   PubMed Web of Science ®Google Scholar
• BUTLER PJ, JONES B. Incidence of characteristics of al-lergic reaction to apraclonidine 0.5%. Invest. Ophthal-mol. Vis. Sci. (1996) 37(3):S201. Abstract 936.
   Google Scholar
• NAGASUBRAMANIAN S, HITCHINGS RA, DEMAILLY P et al.: Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthalmology (1993) 100:1318–1323.
   PubMed Web of Science ®Google Scholar
• MUNK SA, WIESE A, THOMPSON CD et al: Oxidation po-tential and allergic response of ay-agonists. Invest. Oph-thalmol Vis. Sci. (1996) 37:S382. Abstract 3839.
   Google Scholar
• SERDAHL CL, GALUSTIAN J, LEWIS RA: The effects of apraclonidine on conjunctival oxygen tension. Arch. Ophthalmol. (1989) 107:1777–1779.
   PubMed Web of Science ®Google Scholar
• CHANDLER ML, DESANTIS L: Studies of p-amino clo-nidine as a potential antiglaucoma agent. Invest. Oph-thalmol. Vis. Sci. (1985) 26(S3):227. Abstract 93.
   Google Scholar
• FAHRENBACH WH, BACON DR, VAN BUSKIRK EM: Va-soactive drug effects on the uveal vasculature of the rabbit: a corrosion casting study. Invest. Ophthalmol Vis. Sci. (1989) 30(Suppl.):100. Abstract.
   Google Scholar
• BURKE J, MANLAPAZ C, KHARLAMB A et al.: Therapeutic use of ay-adrenoreceptor agonists in glaucoma. In: Al-pha2-Adrenergic Receptors: Structure, Function and Thera-peutic Implications. Lanier S, Limbird L (Eds.), Harwood Academic Publishers, Reading, UK (1996) :179–187.
   Google Scholar
• TORIS CB, CAMRAS CB, YABLONSKI ME: Effects of bri-monidine on aqueous humour dynamics in human eyes. Arch. Ophthalmol. (1995) 113:1514–1517.
   PubMed Web of Science ®Google Scholar
• WILENSKY JT: The role of brimonidine in the treatment of open-angle glaucoma. Surv. Ophthalmol. (1996) 41 (Suppl. 1) :S3–S7.
   Google Scholar
• CANTOR BL, BURKE J: Brimonidine. Exp. Opin. Invest. Drugs (1997) 6(8) :1063–1083.
   PubMedGoogle Scholar
• SCHUMAN JS: Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hyper-tension. Surv. Ophthalmol. (1996) 41:S27–537.
   Google Scholar
• SCHUMAN JS, HORWITZ B, CHOPLIN NT et al.: A 1-year study of brimonidine twice daily in glaucoma and ocu-lar hypertension. A controlled, randomised, multicen-ter clinical trial. Arch. Ophthalmol (1997) 115:847–852.
   PubMed Web of Science ®Google Scholar
• SERLE JB: A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv. Ophthalmol (1996) 41 (Supp1.1):S39–S47.
   Google Scholar
• TRAVERSO CE, FOR THE BRIMONIDINE ADDITIVITY STUDY GROUP I: Additivity of brimonidine 0.2% BID or pilocarpine 2% TID to beta-blocker monotherapy. In-vest. Ophthalmol. Vis. Sci. (1998) 39 (4) :S480. Abstract 2199.
   Google Scholar
• WALTERS TR: Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure; a review of safety, efficacy, dose response and dosing studies. Surv. Ophthalmol. (1996) 41:S19–S26.
   PubMed Web of Science ®Google Scholar
• MUNDORF TK: Brimonidine 0.2% versus betaxolol 0.25% as measured by the clinical success rate and quality of life effects in patients with glaucoma or ocu-lar hypertension. The Brimonidine study group II. In-vest. Ophthalmol Vis. Sci. (1998) 39(4) : (5200) . Abstr. 941.
   Google Scholar
• JAVITT J, FOR THE BRIMONIDINE OUTCOME STUDY GROUP: The clinical success rate and quality of life as-sessment of brimonidine tartrate 0.2% compared with timolol 0.5%, administered twice-daily, in patients with previously untreated open-angle glaucoma or ocular hypertension. Invest. Ophthalmol Vis. Sci. (1997) 38 (4) :S729. Abstract 3363.
   Google Scholar
• CANTOR LB, KATZ LJ, FLARTLEY KJ et al.: Comparison of the effect of Alphagan 0.2% versus Trusopt 2.0% in combination with beta-blockers. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):S480. Abstract 2200. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• MEHTA NH, SIMMONS ST, FOR THE ALPHAGAN/TRU-SOPT STUDY GROUP: The safety and efficacy of brimo-nidine and dorzolamide as concomitant therapy in primary open angle glaucoma and ocular hyperten-sion. Invest. Ophthalmol Vis. Sci. (1998) 39(4):S481. Ab-stract 2202.
   Google Scholar
• NORDLUND JR, PASQUALE LR, ROBIN AL et al.: The car-diovascular, pulmonary, and ocular hypotensive ef-fects of 0.2% brimonidine. Arch. Ophthalmol. (1995) 113:77–83.
   Google Scholar
• THOMPSON CD, MACDONALD TL, GARST ME et al.: Mechanisms of adrenergic agonist induced allergy: bioactivation and antigen formation. Exp. Eye Res. (1997) 64(5):767–773.
   PubMed Web of Science ®Google Scholar
• LACHKAR Y, MIGDAL C, DHANJIL S et al: The effect of brimonidine on ocular blood flow. Invest. Ophthalmol. Vis. Sci. (1997) 38(Suppl.):S778. Abstract 3602.
   Google Scholar
• KATZ BA, PILLUNAT LE, BOHM AG, HAMMARD P, RICH-ARD G: Effect of brimonidine on optic nerve head blood flow. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):S270. Abstract 1230.
   Google Scholar
• KANZOW U, PILLUNAT LE, BOHM AG, KATZ AB, RICH-ARD G: Scanning laser doppler flowmetry after topical brimonidine administration. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):S271. Abstract 1235.
   Google Scholar
• MITCHELL CK, NGUYEN CK, FELDMAN RM: Neuroprotec-tion of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. (1998) 39(05261. Abstract 1187.
   Google Scholar
• ACHEAMPONG AA, SHACKLETON M, TANG-LIU DD-S: Comparative ocular pharmokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab. Dispos. (1995) 23 (7):708–712.
   PubMed Web of Science ®Google Scholar
• CHIEN D-S, RICHMAN J, ZOLEZIO H. Drug distribution of brimonidine in albino and pigmented rabbit eyes. Pharmaceut. Res. (1992) 9(Suppl.):S336. Abstract PPDM 8320.
   Google Scholar
• BURKE J, SCHWARTZ M: Preclinical evaluation of bri-monidine. Sun'. Ophthalmol. (1996) 41 (Suppl.):S9–S18.
   Google Scholar
• LAI RK, CHUN TY, HASSON DW, WHEELER LA, LIU C, WEN R: Brimonidine protects photoreceptors and visual function after light damage. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):5876. Abstract 4066.
   Google Scholar
• MAIER C, STEINBERG GK, SUN GH et al.: Neuroprotec-tion by the alpha-2-adrenoreceptor agonist dexmede-tomidine in a focal model of cerebral ischaemia. Anesthesiology (1993) 79:306–312.
   PubMed Web of Science ®Google Scholar
• REIS DJ, REGUNATHAN S, MEELEY MP: Imidazole recep-tors and clonidine displacing substance in relation-ship to control of blood pressure, neuroprotection, and adrenomedullary secretion. Am. J. Hypertens. (1992) 5:51S–57S.
   Google Scholar
• WEN R, CHENG T, LI Y et al: Induction of bFGF gene ex-pression in vivo in rat photoreceptors by the a2-adrenergic agonists xylazine and clonidine. Soc. Neuro-sci. Abstr. (1995) 21(2, Suppl.):1045. Abstract.
   Google Scholar
• WEN R, CHENG T, LI Y et al. Systemic application of az-a-drenergic agonists xylazine or clonidine induces bFGF expression in photoreceptors. Invest. Ophthalmol. Vis. Sci. (1996) 37 (Suppl.):S436. Abstract 2003.
   Google Scholar
• WOODWARD DF, MADHU C, RIX P, KHARLAMB A: Stud-ies on the ocular effects of a pharmacologically novel agent prostaglandin F2a1-0C113 (AGN 191129). Presen-tation at the International Union Pharmacologists. Munich, Germany (July 1998): (Abstract).
   Google Scholar
• VANDENBURGH AM, LAIBOVITZ RA, FELIX C: A novel Ocular Hypotensive Lipid': initial safety and efficacy of AGN 192024. Invest. Ophthalmol. Vis. Sci. (1998) 39(05258. Abstract 1177.
   Google Scholar
• WOODWARD DF: Ocular Hypotensive Lipids': phar-mocological characterization of a unique series of bio-logically active lipids. Presentation: International Congress Ophthalmologists (June 1998): Amsterdam, Neth-erlands. Abstract.
   Google Scholar
• WOODWARD DF, KRAUSS AH-P, CHEN J etal.: Neutral re-placement of the carboxylic acid group of prostaglan-din F2cc provides a novel series of ocular hypotensive lipids with pharmocological activity distinct from prostanoids. Invest. Ophthalmol. Vis. Sci. (1998) 39(4):5420. Abstract 1962.
   Google Scholar
• WOODWARD DF: Evidence for a novel receptor uniquely sensitive to prostaglandin F2cc analogues containing a neutral substituent for the carboxylic acid group. Presentation: Fed. Am. Soc. Exp. Biol. (April 1998) San Francisco, USA. Abstract.
   Google Scholar
• WOODWARD DE, REGAN JW, LAKE S, OCKLIND A: The molecular biology and ocular distribution of prostanoid receptors. Surv. Ophthalmol. (1997) 41(52):515–521.
   Google Scholar
• OLNEY JW: Glutamate-induced retinal degeneration in neonatal mice: electron microscopy of the acutely evolving lesion. J. Neuropathol. Exp. Neurol. (1969) 28:455–474.
   PubMed Web of Science ®Google Scholar
• LUCAS DR, NEWHOUSE JP: The toxic effect of sodium L-glutamate on the inner layers of the retina. Am. Med. Assoc. Arch. Ophthalmol (1957) 58:193–201.
   PubMed Web of Science ®Google Scholar
• DREYER EB, ZURAKOWSKI D, SCHUMER RA, PODOS SM, LIPTON SA: Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol (1996) 114:299–305.
   PubMed Web of Science ®Google Scholar
• BORMANN J: Memantine is a potent blocker of N-methyl-n-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. (1989) 166(3):591–592.
   PubMed Web of Science ®Google Scholar
• LIPTON SA, ROSENBERG PA: Excitatory amino acids as a final common pathway for neurologic disorders. In: Mechanisms of Disease. Epstein FH (Ed.), New Engl. J. Med. (1994) 330(9):613–622.
   PubMed Web of Science ®Google Scholar
• CHEN HSV, PELLIGRINI JW, AGGARWAL SK et al.: Open channel block of N-methyl-n-aspartate (NMDA) re-sponses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. (1992) 12:4427–4436.
   PubMed Web of Science ®Google Scholar
• CHEN HSV, LIPTON SA: Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. (1997) 499(1)27–46.
   Google Scholar
• REYES M, REYES A, OPITZ T, KAPIN MA, STANTON PK: Eliprodil, a non-competitive, NR2B-selective NMDA antagonist, protects pyramidal neurons in hippocam-pal slices from hypoxic/ischaemic damage. Brain Res. (1998) 782(1-2):212–218.
   PubMed Web of Science ®Google Scholar
• CHANDLER ML, PANG I-H, DOSHI R et al.: In vitro and in vivo protective effects of eliprodil in the retina. Invest. Ophthalmol. Vis. Sci. (1997) 38(4):S147. Abstract 725.
   Google Scholar
• HUBERT JP, DELUMEAU JC, GLOWINSKY J, PREMONT J, DOBLE A: Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured gran-ule cells: evidence for a dual mechanism of action. Br. Pharmacol (1994) 113:261–267.
   PubMed Web of Science ®Google Scholar
• MALGOURIS C, DANIEL M, DOBLE A: Neuroprotective ef-fects of riluzole on N-methyl-u-aspartate or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci. Lett. (1994) 113:10–17.
   Google Scholar
• RAGAIEY T, MA JX, JIANG WJ et al.: L-Deprenyl protects injured retinal precursor cells in vitro. J. Ocul. Pharma-col. Ther. (1997) 13(5):479–488.
   PubMed Web of Science ®Google Scholar
• YUI SC, JOLLIMORE CA, TATTON N, KELLEY MEM: (-)- De-prenyl increases cell survival and decreases apoptosis in rat retinal cultures following trophic withdrawal. Invest. Ophthalmol. Vis. Sci. (1997) 38(4):S159. Abstract 788.
   Google Scholar
• STOILOV I, AKARSU AN, SARFARAZI M: Identification of three different truncated mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. (1997) 6(4):641–647.
   PubMed Web of Science ®Google Scholar
• BREZIN AP, MONDON H, GARCHON H-J: Molecular ge-netics of open-angle glaucoma, moving from gene lo-calization to predictive testing. Curr. Opin. Ophthalmol. (1997) 8(2):13–18.
   PubMedGoogle Scholar
• NGUYEN TD, CHEN P, HUANG WD et al.: Gene structure and properties of TIGR, an olfactin-related glycoprotein cloned from glucocorticoid-induced tra-becular meshwork cells. J. Biol. Chem. (1998) 273(106341–6350.
   Web of Science ®Google Scholar
• WAX MB: Is there evidence for autoimmune-mediated glaucomatous neuropathy? 2nd International Glaucoma Symposium. Handbook (1998):96. Abstract.
   Google Scholar
• KOSEKI Y, KITANO S, PODOS SM, MITTAG T, CAPRIOLI J: A nitric oxide synthase inhibitor protects against an-oxia in cultured rat retinal ganglion cells. Invest. Oph-thalmol. Vis. ScL (1994) 35:1968.
   Web of Science ®Google Scholar
• BLOCK F, SCHWARZ M: The b-wave of the electroretina-gram as an index of retinal ischaemia. Gen. Pharmacol (1998) 30(3):281–287.
   PubMedGoogle Scholar
• NICKELLS RW, ZACK DJ: Apoptosis in ocular disease: a molecular overview. Ophthalmic Genet. (1996) 17 (4):145–65.
   PubMed Web of Science ®Google Scholar
• MEYER-FRANKE A, KAPLAN MR, PFRIEGER FW, BARRES BA: Characterization of the signalling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron (1995) 15:805–819.
   PubMed Web of Science ®Google Scholar
• HICKS D, HEIDINGER V, MOHAND-SAID S, SAHEL J, DREYFUS H: Growth factors and gangliosides as neuro-protective agents in excitotoxicity and ischemia. Gen. Pharmacol. (1998) 30(30265–273.
   Google Scholar
• LAVAIL MW, YASUMURA D, MATHES MT et al: Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest. Ophthalmol. Vis. Sci. (1998) 39(3)592–602.
   Google Scholar